BMY240628C43000
- 0.02
- 0.000.00%
Bristol-Myers Squibb Newsroom
Bristol-Myers Squibb (BMY) Gets a Hold From Wells Fargo
Wells Fargo Reaffirms Their Hold Rating on Bristol-Myers Squibb (BMY)
Analysts Offer Insights on Healthcare Companies: Lyra Therapeutics (LYRA), Bristol-Myers Squibb (BMY) and Axsome Therapeutics (AXSM)
HSBC Adjusts Price Target on Bristol-Myers Squibb to $45 From $50
Deutsche Bank Adjusts Price Target on Bristol-Myers Squibb to $53 From $55, Keeps Hold Rating
Bank of Montreal, Canada: Maintaining the Bristol-Myers Squibb (BMY.US) rating, adjusted from a consistent market rating to a consistent market rating, and the target price was adjusted from $55.00 to $48.00.
Bristol-Myers Squibb Analyst Ratings
BMO Capital Adjusts Price Target on Bristol-Myers Squibb Company to $48 From $55
Analysts Offer Insights on Healthcare Companies: Universal Health (UHS), Laboratory (LH) and Bristol-Myers Squibb (BMY)
Bristol-Myers Squibb: Hold Rating Amid Mixed Performance and Future Revenue Concerns
Barclays Sticks to Their Hold Rating for Bristol-Myers Squibb (BMY)
Cantor Fitzgerald Adjusts Price Target on Bristol-Myers Squibb to $45 From $52, Maintains Neutral Rating
Bristol-Myers Squibb: A Hold Rating Amid Mixed Financial Outlook and Upcoming Strategic Updates
Bristol-Myers Squibb Analyst Ratings
Wells Fargo Maintains Equal-Weight on Bristol-Myers Squibb, Raises Price Target to $52
Analysts' Opinions Are Mixed on These Healthcare Stocks: Accolade (ACCD), Ultragenyx Pharmaceutical (RARE) and Bristol-Myers Squibb (BMY)
Jefferies Cuts Bristol-Myers Squibb's Price Target to $56 From $58
Analysts Have Conflicting Sentiments on These Healthcare Companies: Bristol-Myers Squibb (BMY) and Roche Holding AG (OtherRHHVF)
Bristol-Myers Squibb: A Buy Rating on Undervaluation and Promising Product Portfolio
Hold Rating on Bristol-Myers Squibb Amid Promising Yet Incomplete KarXT Schizophrenia Trial Data